A resolution designating September 2026 as "National Cholesterol Education Month" and September 30, 2026, as "LDL-C Awareness Day".

Cindy Hyde-Smith

Republican · MS · Senator

Source: Congress.gov · FEC

• Alex Padilla (D-CA)Original· 2026-09-28
• Gary C. Peters (D-MI)Original· 2026-09-28
• Katie Boyd Britt (R-AL)Original· 2026-09-28

Submitted in the Senate, considered, and agreed to without amendment and with a preamble by Unanimous Consent. (consideration: CR S5123; text: CR S5075)

2026-09-28

Source: Congress.gov

Plain-English summary pending. Introduced on 2026-09-28. Check back soon — summaries are generated as bills progress through Congress.

[Congressional Bills 119th Congress] [From the U.S. Government Publishing Office] [S. Res. 914 Agreed to Senate (ATS)] <DOC> 119th CONGRESS 2d Session S. RES. 914 Designating September 2026 as ``National Cholesterol Education Month'' and September 30, 2026, as ``LDL-C Awareness Day''. _______________________________________________________________________ IN THE SENATE OF THE UNITED STATES September 28, 2026 Mrs. Hyde-Smith (for herself, Mr. Peters, Mrs. Britt, and Mr. Padilla) submitted the following resolution; which was considered and agreed to _______________________________________________________________________ RESOLUTION Designating September 2026 as ``National Cholesterol Education Month'' and September 30, 2026, as ``LDL-C Awareness Day''. Whereas cardiovascular disease is the leading cause of death for men and women in the United States; Whereas more than 184,000,000 people in the United States are projected to have some type of cardiovascular disease by 2050, and total cardiovascular disease-related costs are projected to triple to $1,800,000,000,000; Whereas, compared to urban areas, rural areas in the United States have higher death rates for cardiovascular disease and stroke and a 40 percent higher prevalence of cardiovascular disease; Whereas risk factors contributing to cardiovascular disease and poor health outcomes include elevated low-density lipoprotein cholesterol (referred to in this preamble as ``LDL-C'' ), high levels of lipoprotein(a) cholesterol, hypertension, obesity, low awareness of personal risk factors, genetics, geographic location, and disparities in access to care; Whereas lipoprotein(a) cholesterol is predominantly genetically inherited and can build up in the walls of blood vessels, creating cholesterol deposits, or plaques, and lead to atherosclerotic cardiovascular disease; Whereas clinical guidelines recommend that adults in the United States should have a lipoprotein(a) test at least once in their lifetime for cardiovascular risk assessment; Whereas LDL-C is a modifiable risk factor for cardiovascular disease, and having lower LDL-C is associated with a reduced risk of atherosclerotic cardiovascular disease, including heart attack and stroke, which are the leading causes of cardiovascular-related mortality; Whereas more than 25.5 percent of adults in the United States have high LDL-C; Whereas more than 200 studies with more than 2,000,000 patients have broadly established that elevated LDL-C causes atherosclerotic cardiovascular disease; Whereas atherosclerotic cardiovascular disease is the build-up of cholesterol plaque within the walls of arteries and includes acute coronary syndrome, peripheral arterial disease, and events such as heart attacks and strokes; Whereas the resources needed to bend the curve on cardiovascular disease exist, yet fewer than 1 in 4 adults with high-risk atherosclerotic cardiovascular disease in the United States achieve guideline- recommended LDL-C targets; Whereas only 33 percent of individuals with atherosclerotic cardiovascular disease who are taking statins, a guideline recommended lipid-lowering therapy, actually achieve LDL-C goals; Whereas, although clinical guidelines recommend that a patient hospitalized for heart attack receive an LDL-C test in the 90 days following discharge from a hospital, only 27 percent of patients receive the test; Whereas African-American adults are less likely to receive an LDL-C test in the 90 days following discharge from a hospital, despite having a higher prevalence of cardiovascular disease; Whereas significant gaps in care may lead to subsequent cardiovascular events; Whereas Federal agencies seek to improve access to and quality of care to reduce heart disease, stroke, and death; and Whereas September is recognized as National Cholesterol Education Month to raise awareness of cardiovascular disease and the importance of individuals knowing their LDL-C number: Now, therefore, be it Resolved, That the Senate-- (1) encourages all individuals in the United States to know their low density lipoprotein cholesterol (referred to in this resolution as ``LDL-C'') number; (2) designates September 2026 as ``National Cholesterol Education Month''; (3) designates September 30, 2026, as ``LDL- C Awareness Day''; and (4) recognizes the urgent need for screening and…

treating of elevated LDL-C to reduce the risk of cardiovascular disease and cardiovascular events, including heart attacks and strokes. <all>

• S5613Ecuador Shrimp Tariff Act
  Referred to Committee · 2026-09-30
• SRES904A resolution designating the week of September 20 through September 27, 2026, as "Gold Star Families Remembrance Week".
  Introduced · 2026-09-24
• SRES894A resolution designating September 25, 2026, as "National Ataxia Awareness Day", and raising awareness of ataxia, ataxia research, and the search for a cure.
  Introduced · 2026-09-23
• S5364Rural Mothers and Fathers Choice Act
  Referred to Committee · 2026-08-07